PolTREG receives CGMP certification to produce cell therapies at its state-of-the-art manufacturing site in Poland Gdańsk, Poland – 11 March 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces it...

PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes               Gdańsk, Poland – 16 January 2024, 07:00 CET – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company in Europe developing cell therapies for use in a wide...